Clinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution
Authors:
- Philipp Hoegen-SaßmannshausenPHPhilipp Hoegen-Saßmannshausen
- Inga JessenIJInga Jessen
- Carolin BucheleCBCarolin Buchele
- Fabian SchlüterFSFabian Schlüter
- Carolin RippkeCRCarolin Rippke
- Claudia Katharina RenkampCRClaudia Katharina Renkamp
- Fabian WeykampFabian Weykamp
- Sebastian RegnerySRSebastian Regnery
- Jakob LiermannJLJakob Liermann
- Eva MeixnerEMEva Meixner
- Line HoeltgenLHLine Hoeltgen
- Tanja EichkornTETanja Eichkorn
Open Access
Abstract
(1) Background: Recent publications foster stereotactic body radiotherapy (SBRT) in patients with adrenal oligometastases or oligoprogression. However, local control (LC) after non-adaptive SBRT shows the potential for improvement. Online adaptive MR-guided SBRT (MRgSBRT) improves tumor coverage and organ-at-risk (OAR) sparing. Long-term results of adaptive MRgSBRT are still sparse. (2) Methods: Adaptive MRgSBRT was performed on a 0.35 T MR-Linac. LC, overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity were assessed. (3) Results: 35 patients with 40 adrenal metastases were analyzed. The median gross tumor volume was 30.6 cc. The most common regimen was 10 fractions at 5 Gy. The median biologically effective dose (BED10) was 75.0 Gy. Plan adaptation was performed in 98% of all fractions. The median follow-up was 7.9 months. One local failure occurred after 16.6 months, resulting in estimated LC rates of 100% at one year and 90% at two years. ORR was 67.5%. The median OS was 22.4 months, and the median PFS was 5.1 months. No toxicity > CTCAE grade 2 occurred. (4) Conclusions: LC and ORR after adrenal adaptive MRgSBRT were excellent, even in a cohort with comparably large metastases. A BED10 of 75 Gy seems sufficient for improved LC in comparison to non-adaptive SBRT.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DE 614/16-1, DE 614/16-1)
- Deutsche Forschungsgemeinschaft (DE 614/16-1, DE 614/16-1)
This publication has 35 references indexed in Scilit:
- Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastasesClinical and Translational Radiation Oncology, 2024
- Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastasesClinical and Translational Radiation Oncology, 2024
- Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at riskClinical and Translational Radiation Oncology, 2023
- Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at riskClinical and Translational Radiation Oncology, 2022
- Stereotactic body radiotherapy of adrenal metastases—A dose‐finding studyInternational Journal of Cancer, 2022
- UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative RadiotherapyClinical Oncology, 2022
- Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysisInternational Journal of Cancer, 2021
- Magnetresonanzgeführte StrahlentherapieDer Radiologe, 2020
- RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupEuropean Journal of Cancer, 2016
- Metastases in carcinoma.Analysis of 1000 autopsied casesCancer, 1950